Natural Capsules Ltd

Natural Capsules Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Natural Capsules Ltd

₹ 154 6.65%
01 Apr 4:01 p.m.
naturalcapsules.com BSE: 524654 NSE: NATCAPSUQ
About

Incorporated in 1993, Natural Capsules manufactures Capsules and Steroidal APIs and their Intermediates and Derivatives[1]

Key Points

Business Overview:[1][2][3]
NCL is a WHO-GMP certified and ISO 9001, ISO 140001 compliance manufacturer of printed and unprinted hard two-piece Gelatin and Cellulose (HPMC : non-animal alternative) capsules for pharmaceutical and dietary supplement industries in various sizes of 00, 0el, 0, 1, 2, 3 & 4. Apart from this, NCL has forayed into API manufacturing with complex high-end patented technology developed in-house, under its subsidiary company Natural Biogenex Private Limited.

Website BSE NSE
  • Market Cap ₹ 160 Cr.
  • Current Price ₹ 154
  • High / Low ₹ 296 / 136
  • Stock P/E
  • Book Value ₹ 237
  • Dividend Yield 0.00 %
  • ROCE 2.67 %
  • ROE 0.28 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Stock is trading at 0.68 times its book value

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has low interest coverage ratio.
  • Company has a low return on equity of 5.07% over last 3 years.
  • Contingent liabilities of Rs.70.8 Cr.
  • Company might be capitalizing the interest cost
  • Earnings include an other income of Rs.1.27 Cr.
  • Promoter holding has decreased over last 3 years: -5.30%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
45.50 37.62 37.70 37.52 39.98 40.22 39.18 41.22 43.83 44.97 45.20 45.80 37.75
35.84 31.85 31.74 32.40 35.26 36.11 34.81 36.72 39.56 40.58 44.88 46.69 40.07
Operating Profit 9.66 5.77 5.96 5.12 4.72 4.11 4.37 4.50 4.27 4.39 0.32 -0.89 -2.32
OPM % 21.23% 15.34% 15.81% 13.65% 11.81% 10.22% 11.15% 10.92% 9.74% 9.76% 0.71% -1.94% -6.15%
0.05 0.21 0.17 0.35 0.50 0.92 0.18 0.11 0.11 0.30 0.36 0.16 0.45
Interest 0.95 1.12 1.33 1.16 1.24 1.40 1.49 1.65 1.54 1.64 2.53 2.68 2.85
Depreciation 1.74 1.87 2.11 2.17 2.19 2.20 2.28 2.35 2.33 2.16 4.21 4.29 4.36
Profit before tax 7.02 2.99 2.69 2.14 1.79 1.43 0.78 0.61 0.51 0.89 -6.06 -7.70 -9.08
Tax % 25.21% 40.13% 32.34% 27.10% 32.96% 32.17% 21.79% 201.64% 78.43% 41.57% -8.09% -9.09% -21.70%
5.25 1.79 1.82 1.56 1.21 0.97 0.60 -0.61 0.11 0.52 -5.58 -6.99 -7.12
EPS in Rs 5.65 1.94 1.96 1.68 1.30 1.04 0.64 -0.60 0.11 0.50 -5.40 -6.76 -6.89
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
55 60 62 80 135 170 155 169 174
49 55 56 68 110 135 134 151 172
Operating Profit 6 5 5 11 26 35 20 18 1
OPM % 10% 8% 9% 14% 19% 21% 13% 10% 1%
1 1 1 3 1 1 2 1 1
Interest 0 1 1 1 2 4 5 7 10
Depreciation 4 3 4 4 5 7 9 9 15
Profit before tax 2 2 1 9 19 25 8 3 -22
Tax % 34% 7% 38% 24% 28% 26% 31% 78%
1 2 1 7 14 18 6 1 -19
EPS in Rs 1.19 2.06 0.92 7.43 14.96 20.02 5.95 0.60 -18.55
Dividend Payout % 56% 32% 43% 9% 5% 5% -0% -0%
Compounded Sales Growth
10 Years: %
5 Years: 22%
3 Years: 8%
TTM: 6%
Compounded Profit Growth
10 Years: %
5 Years: -6%
3 Years: -65%
TTM: -1892%
Stock Price CAGR
10 Years: 5%
5 Years: 10%
3 Years: -28%
1 Year: -24%
Return on Equity
10 Years: %
5 Years: 7%
3 Years: 5%
Last Year: 0%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 6 6 6 6 7 9 9 10 10
Reserves 48 49 49 56 76 114 194 223 235
-0 5 6 10 53 97 109 105 112
19 14 14 26 29 70 64 81 62
Total Liabilities 73 75 76 99 165 290 377 419 420
22 24 24 38 66 97 103 284 281
CWIP 1 2 2 7 20 88 144 -0 1
Investments 5 5 6 -0 0 -0 3 3 3
45 43 45 54 79 105 127 133 135
Total Assets 73 75 76 99 165 290 377 419 420

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
5 2 7 6 -1 17 -8 27
-1 -7 -6 -9 -46 -105 -73 -44
-4 4 -1 3 48 87 82 16
Net Cash Flow 0 -1 0 -0 1 0 1 -2
Free Cash Flow 4 -5 2 -11 -47 -88 -79 -18
CFO/OP 97% 57% 144% 72% 17% 64% -32% 162%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 208 197 180 123 71 112 129 134
Inventory Days 149 87 89 82 34 45 88 109
Days Payable 185 114 91 157 98 127 141 166
Cash Conversion Cycle 172 170 179 48 7 30 76 78
Working Capital Days 186 143 121 75 73 61 80 53
ROCE % 5% 4% 11% 21% 15% 5% 3%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Annual Production Capacity (Capsules)
Billion Capsules ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Capacity Utilization (Capsules)
% ・Standalone data
Number of Employees
Count
Production Volume (Capsules)
Billion Capsules ・Standalone data
Sales Volume (Capsules)
Billion Capsules ・Standalone data
Number of Customers
Count
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Shareholding Pattern

Numbers in percentages

6 Recently
Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
56.57% 56.57% 56.57% 56.57% 56.57% 56.57% 51.59% 51.13% 51.21% 51.26% 51.26% 51.26%
1.31% 1.31% 1.31% 1.31% 1.31% 0.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
42.13% 42.13% 42.13% 42.13% 42.13% 43.25% 48.39% 48.86% 48.80% 48.75% 48.73% 48.74%
No. of Shareholders 8,66610,80511,67511,39910,95410,5149,8629,6619,4259,3119,5739,075

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls